Login Register Cart 0
Generic placeholder image

Cardiovascular & Hematological Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5257
ISSN (Online): 1875-6182

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Anticoagulation in Atrial Fibrillation Associated with Mitral Stenosis

Author(s): Rose Mary Ferreira Lisboa da Silva*

Volume 20, Issue 3, 2022

Published on: 21 April, 2022

Page: [172 - 174] Pages: 3

DOI: 10.2174/1871525720666220321120944

open access plus

Abstract

Rheumatic valve disease is present in 0.4 % of the word population, mainly in lowincome countries. Rheumatic mitral stenosis affects more women and between 40 to 75 % of patients may have atrial fibrillation (AF), more frequently in upper-middle income countries. This rhythm disturbance is due to increased atrial pressure, chronic inflammation, fibrosis, and left atrial enlargement. There is also an increase in the prevalence of AF with age in patients with mitral stenosis. The risk of stroke is 4 % per year. Success rates for cardioversion, Cox-Maze procedure, and catheter ablation are low. Therefore, anticoagulation with vitamin K antagonist is mandatory for Evaluated Heart valves, Rheumatic or Artificial (EHRA) classification type 1. However, this anticoagulation is used by less than 80 % of those eligible and less than 30 % have the international normalized ratio in the therapeutic range. The safety and efficacy of using rivaroxaban, a direct factor Xa inhibitor anticoagulant, were demonstrated in the RIVER trial with a sample of 1005 patients with AF and bioprosthetic mitral valve. The indication for valve replacement, that is, if severe mitral stenosis or severe mitral regurgitation, was not specified. A randomized, open-label study (DAVID-MS) is underway to compare the effectiveness and safety of dabigatran and warfarin therapy for stroke prevention in patients with AF and moderate or severe mitral stenosis. Thus, the applicability of the use of direct anticoagulants in patients with AF and mitral stenosis and also in those undergoing mitral bioprostheses surgery will be the subject of further studies. The findings may explain if specific atrial changes of mitral stenosis even after the valve replacement will influence thromboembolic events with direct anticoagulants.

Keywords: Atrial fibrillation, anticoagulation, mitral stenosis, rheumatic heart disease, non-vitamin K oral anticoagulants, bioprosthetic heart valves.

« Previous Next »
[1]
Coffey, S.; Roberts-Thomson, R.; Brown, A.; Carapetis, J.; Chen, M.; Enriquez-Sarano, M.; Zühlke, L.; Prendergast, B.D. Global epidemiology of valvular heart disease. Nat. Rev. Cardiol., 2021, 18(12), 853-864.
[http://dx.doi.org/10.1038/s41569-021-00570-z] [PMID: 34172950]
[2]
Marijon, E.; Mocumbi, A.; Narayanan, K.; Jouven, X.; Celermajer, D.S. Persisting burden and challenges of rheumatic heart disease. Eur. Heart J., 2021, 42(34), 3338-3348.
[http://dx.doi.org/10.1093/eurheartj/ehab407] [PMID: 34263296]
[3]
Watkins, D.A.; Beaton, A.Z.; Carapetis, J.R.; Karthikeyan, G.; Mayosi, B.M.; Wyber, R.; Yacoub, M.H.; Zühlke, L.J. Rheumatic heart dis-ease worldwide: JACC scientific expert panel. J. Am. Coll. Cardiol., 2018, 72(12), 1397-1416.
[http://dx.doi.org/10.1016/j.jacc.2018.06.063] [PMID: 30213333]
[4]
Kumar, R.K.; Antunes, M.J.; Beaton, A.; Mirabel, M.; Nkomo, V.T.; Okello, E.; Regmi, P.R.; Reményi, B.; Sliwa-Hähnle, K.; Zühlke, L.J.; Sable, C. American heart association council on lifelong congenital heart disease and heart health in the young; council on cardiovascular and stroke nursing; and council on clinical cardiology. contemporary diagnosis and management of rheumatic heart disease: Implications for closing the gap: A scientific statement from the American heart association. Circulation, 2020, 142(20), e337-e357.
[http://dx.doi.org/10.1161/CIR.0000000000000921] [PMID: 33073615]
[5]
Noubiap, J.J.; Nyaga, U.F.; Ndoadoumgue, A.L.; Nkeck, J.R.; Ngouo, A.; Bigna, J.J. Meta-analysis of the incidence, prevalence, and correlates of atrial fibrillation in rheumatic heart disease. Glob. Heart, 2020, 15(1), 38.
[http://dx.doi.org/10.5334/gh.807] [PMID: 32923332]
[6]
Zühlke, L.; Karthikeyan, G.; Engel, M.E.; Rangarajan, S.; Mackie, P.; Cupido-Katya Mauff, B.; Islam, S.; Daniels, R.; Francis, V.; Ogendo, S.; Gitura, B.; Mondo, C.; Okello, E.; Lwabi, P.; Al-Kebsi, M.M.; Hugo-Hamman, C.; Sheta, S.S.; Haileamlak, A.; Daniel, W.; Goshu, D.Y.; Abdissa, S.G.; Desta, A.G.; Shasho, B.A.; Begna, D.M.; ElSayed, A.; Ibrahim, A.S.; Musuku, J.; Bode-Thomas, F.; Yilgwan, C.C.; Amusa, G.A.; Ige, O.; Okeahialam, B.; Sutton, C.; Misra, R.; Abul Fadl, A.; Kennedy, N.; Damasceno, A.; Sani, M.U.; Ogah, O.S.; Elhassan, T.O.; Mocumbi, A.O.; Adeoye, A.M.; Mntla, P.; Ojji, D.; Mucumbitsi, J.; Teo, K.; Yusuf, S.; Mayosi, B.M. Clinical outcomes in 3343 children and adults with rheumatic heart disease from 14 Low- and middle-income countries: two-year follow-up of the global rheumatic heart dis-ease registry (the remedy study). Circulation, 2016, 134(19), 1456-1466.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024769] [PMID: 27702773]
[7]
Iung, B.; Leenhardt, A.; Extramiana, F. Management of atrial fibrillation in patients with rheumatic mitral stenosis. Heart, 2018, 104(13), 1062-1068.
[http://dx.doi.org/10.1136/heartjnl-2017-311425] [PMID: 29453328]
[8]
Guo, Q.; Yan, F.; Ouyang, P.; Xie, Z.; Wang, H.; Yang, W.; Pan, X. Bi-atrial or left atrial ablation of atrial fibrillation during concomitant cardiac surgery: A Bayesian network meta-analysis of randomized controlled trials. J. Cardiovasc. Electrophysiol., 2021, 32(8), 2316-2328.
[http://dx.doi.org/10.1111/jce.15127] [PMID: 34164872]
[9]
Steffel, J.; Collins, R.; Antz, M.; Cornu, P.; Desteghe, L.; Haeusler, K.G.; Oldgren, J.; Reinecke, H.; Roldan-Schilling, V.; Rowell, N.; Sin-naeve, P.; Vanassche, T.; Potpara, T.; Camm, A.J.; Heidbüchel, H. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace, 2021, 23(10), 1612-1676.
[http://dx.doi.org/10.1093/europace/euab065] [PMID: 33895845]
[10]
Ramakumar, V.; Benz, A.P.; Karthikeyan, G. Long-term oral anticoagulation for atrial fibrillation in low and middle income countries. Indian Heart J., 2021, 73(2), 244-248.
[http://dx.doi.org/10.1016/j.ihj.2021.02.003] [PMID: 33865530]
[11]
Guimarães, H.P.; Lopes, R.D.; de Barros, E. Silva, P.G.M.; Liporace, I.L.; Sampaio, R.O.; Tarasoutchi, F.; Hoffmann-Filho, C.R.; de Lemos Soares Patriota, R.; Leiria, T.L.L.; Lamprea, D.; Precoma, D.B.; Atik, F.A.; Silveira, F.S.; Farias, F.R.; Barreto, D.O.; Almeida, A.P.; Zilli, A.C.; de Souza Neto, J.D.; Cavalcante, M.A.; Figueira, F.A.M.S.; Kojima, F.C.S.; Damiani, L.; Santos, R.H.N.; Valeis, N.; Campos, V.B.; Saraiva, J.F.K.; Fonseca, F.H.; Pinto, I.M.; Magalhães, C.C.; Ferreira, J.F.M.; Alexander, J.H.; Pavanello, R.; Cavalcanti, A.B.; Berwanger, O. RIVER Trial Investigators. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N. Engl. J. Med., 2020, 383(22), 2117-2126.
[http://dx.doi.org/10.1056/NEJMoa2029603] [PMID: 33196155]
[12]
Karthikeyan, G.; Connolly, S.J.; Ntsekhe, M.; Benz, A.; Rangarajan, S.; Lewis, G.; Yun, Y.; Sharma, S.K.; Maklady, F.; Elghamrawy, A.E.; Kazmi, K.; Cabral, T.T.J.; Dayi, H.; Changsheng, M.; Gitura, B.M.; Avezum, A.; Zuhlke, L.; Lwabi, P.; Haileamlak, A.; Ogah, O.; Chillo, P.; Paniagua, M.; ElSayed, A. Dans, A.; Gondwe-Chunda, L.; Molefe-Baikai, O.J.; Gonzalez-Hermosillo, J.A.; Hakim, J.; Damasceno, A.; Kamanzi, E.R.; Musuku, J.; Davletov, K.; Connolly, K.; Mayosi, B.M.; Yusuf, S. INVICTUS Investigators. The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. Am. Heart J., 2020, 225, 69-77.
[http://dx.doi.org/10.1016/j.ahj.2020.03.018] [PMID: 32474206]
[13]
Zhou, M.; Chan, E.W.; Hai, J.J.; Wong, C.K.; Lau, Y.M.; Huang, D.; Lam, C.C.; Tam, C.C.F.; Wong, Y.T.A.; Yung, S.Y.A.; Chan, K.W.K.; Feng, Y.; Tan, N.; Chen, J.Y.; Yung, C.Y.; Lee, K.L.; Choi, C.W.; Lam, H.; Ng, A.; Fan, K.; Jim, M.H.; Yiu, K.H.; Yan, B.P.; Siu, C.W. Pro-tocol, rationale and design of DAbigatran for stroke prevention in atrial fibrillation in moderate or severe mitral stenosis (DAVID-MS): A randomised, open-label study. BMJ Open, 2020, 10(9), e038194.
[http://dx.doi.org/10.1136/bmjopen-2020-038194] [PMID: 32978200]
[14]
Rivoraxaban in Mitral Stenosis (RISE MS). ClinicalTrials.gov Identifier: NCT03926156. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03926156?cond=NCT03926156
[15]
Investigation of rheumatiC AF treatment using vitamin K antagonists, rivaroxaban or aspirin studies, superiority (INVICTUS-ASA). ClinicalTrials.gov Identifier: NCT02832531. 2020. Available from: clinicaltrals.gov/ct2/show/NCT02832531?cond=NCT02832531
[16]
John, B.; Stiles, M.K.; Kuklik, P.; Chandy, S.T.; Young, G.D.; Mackenzie, L.; Szumowski, L.; Joseph, G.; Jose, J.; Worthley, S.G.; Kalman, J.M.; Sanders, P. Electrical remodelling of the left and right atria due to rheumatic mitral stenosis. Eur. Heart J., 2008, 29(18), 2234-2243.
[http://dx.doi.org/10.1093/eurheartj/ehn329] [PMID: 18621772]
[17]
Hu, Y.F.; Chen, Y.J.; Lin, Y.J.; Chen, S.A. Inflammation and the pathogenesis of atrial fibrillation. Nat. Rev. Cardiol., 2015, 12(4), 230-243.
[http://dx.doi.org/10.1038/nrcardio.2015.2] [PMID: 25622848]

Rights & Permissions Print Cite
Article Metrics
50
3
© 2024 Bentham Science Publishers | Privacy Policy